WGS250502P85000
- 19.08
- -1.32-6.47%
GeneDx Holdings Newsroom
Jefferies Maintains GeneDx Holdings(WGS.US) With Hold Rating, Raises Target Price to $80
Analysts Have Conflicting Sentiments on These Healthcare Companies: GeneDx Holdings (WGS) and Dexcom (DXCM)
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Cuts Target Price to $110
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Cuts Target Price to $100
GeneDx Holdings Price Target Cut to $110.00/Share From $135.00 by TD Securities
GeneDx Holdings Is Maintained at Buy by TD Securities
GeneDx Holdings Analyst Ratings
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Lowers Price Target to $78
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Xencor (XNCR) and GeneDx Holdings (WGS)
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $115
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), GeneDx Holdings (WGS) and Teva Pharmaceutical (TEVA)
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating, Announces Target Price $114
Craig-Hallum Sticks to Their Buy Rating for GeneDx Holdings (WGS)
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $115
BTIG Sticks to Its Buy Rating for GeneDx Holdings (WGS)
Craig-Hallum Maintains GeneDx Holdings(WGS.US) With Buy Rating
BTIG Maintains GeneDx Holdings(WGS.US) With Buy Rating, Maintains Target Price $115
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), GeneDx Holdings (WGS) and Bausch + Lomb Corporation (BLCO)
GeneDx Hldgs Analyst Ratings
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $135